ScholarIQanswers from OpenAlex
Institut de Cancérologie de Bourgogne
InstitutionResearch output, impact & collaborations
Institut de Cancérologie de Bourgogne is a institution indexed in ScholarIQ from OpenAlex.
What is known about Institut de Cancérologie de Bourgogne?
ScholarIQrecord summary
Institut de Cancérologie de Bourgogne is a research organisation in Auxerre, France. OpenAlex records 408 works and 4,911 citations for it. 1 researchers list it as their most recent affiliation.
How many works does Institut de Cancérologie de Bourgogne have?
ScholarIQindexed works
Institut de Cancérologie de Bourgogne has 408 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Institut de Cancérologie de Bourgogne have?
ScholarIQcitation count
Institut de Cancérologie de Bourgogne has 4,911 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Institut de Cancérologie de Bourgogne?
ScholarIQresearcher count
Institut de Cancérologie de Bourgogne has 1 researchers in the ScholarIQ index.
What is the average h-index at Institut de Cancérologie de Bourgogne?
ScholarIQavg h-index
Institut de Cancérologie de Bourgogne has an average h-index of 78 in OpenAlex.
What is the ROR of Institut de Cancérologie de Bourgogne?
ScholarIQror
The ROR for Institut de Cancérologie de Bourgogne is on the source record.
What is the OpenAlex record for Institut de Cancérologie de Bourgogne?
ScholarIQopenalex
The OpenAlex for Institut de Cancérologie de Bourgogne is on the source record.
Who are the most-cited researchers behind Institut de Cancérologie de Bourgogne?
ScholarIQtop researchers by citations
What are the most-cited papers on Institut de Cancérologie de Bourgogne?
ScholarIQmost cited works
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Michel Attal, Valérie Lauwers‐Cancès, Cyrille Hulin, Xavier Leleu, Denis Caillot, Martine Escoffre, Bertrand Arnulf, Margaret Macro, Karim Belhadj, Laurent Garderet, Murielle Roussel, Catherine Payen, Claire Mathiot, Jean Paul Fermand, Nathalie Meuleman, Sandrine Rollet, Michelle E. Maglio, Andrea A. Zeytoonjian, Edie Weller, Nikhil C. Munshi, Kenneth C. Anderson, Paul G. Richardson, Thierry Façon, Hervé Avet‐Loiseau, Jean‐Luc Harousseau, Philippe Moreau
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
Philippe Moreau, Michel Attal, Cyrille Hulin, Bertrand Arnulf, Karim Belhadj, Lotfi Benboubker, Marie C. Béné, Annemiek Broijl, Hélène Caillon, Denis Caillot, Jill Corre, Michel Delforge, Thomas Dejoie, Chantal Doyen, Thierry Façon, Cécile Sonntag, Jean Fontan, Laurent Garderet, Kon‐Siong G. Jie, Lionel Karlin, Frédérique Kuhnowski, Jérôme Lambert, Xavier Leleu, Pascal Lenain, Margaret Macro, Claire Mathiot, Frédérique Orsini‐Piocelle, Aurore Perrot, Anne‐Marie Stoppa, Niels W.C.J. van de Donk, Soraya Wuillème, Sonja Zweegman, Brigitte Kolb, Cyrille Touzeau, Murielle Roussel, Mourad Tiab, Jean‐Pierre Marolleau, Nathalie Meuleman, Marie‐Christiane Vekemans, Matthijs Westerman, Saskia K. Klein, Mark‐David Levin, Jean Paul Fermand, Martine Escoffre‐Barbe, Jean‐Richard Eveillard, Réda Garidi, Tahamtan Ahmadi, Sen Hong Zhuang, Christopher Chiu, Lixia Pei, Carla de Boer, Elena Smith, William Deraedt, Tobias Kampfenkel, Jordan M. Schecter, Jessica Vermeulen, Hervé Avet‐Loiseau, Pieter Sonneveld
Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies
Denis Caillot, Anne Thiébaut, Raoul Herbrecht, Stéphane de Botton, Arnaud Pigneux, Frédéric Bernard, Jérôme Larché, Françoise Monchecourt, S. Alfandari, L. Mahi
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial
Philippe Moreau, Cyrille Hulin, Aurore Perrot, Bertrand Arnulf, Karim Belhadj, Lotfi Benboubker, Marie C. Béné, Sonja Zweegman, Hélène Caillon, Denis Caillot, Jill Corre, Michel Delforge, Thomas Dejoie, Chantal Doyen, Thierry Façon, Cécile Sonntag, Jean Fontan, Mohamad Mohty, Kon‐Siong G. Jie, Lionel Karlin, Frédérique Kuhnowski, Jérôme Lambert, Xavier Leleu, Margaret Macro, Frédérique Orsini-Piocelle, Murielle Roussel, Anne‐Marie Stoppa, Niels W.C.J. van de Donk, Soraya Wuillème, Annemiek Broijl, Cyrille Touzeau, Mourad Tiab, Jean‐Pierre Marolleau, Nathalie Meuleman, Marie‐Christiane Vekemans, Matthijs Westerman, Saskia K. Klein, Mark‐David Levin, Fritz Offner, Martine Escoffre‐Barbe, Jean‐Richard Eveillard, Réda Garidi, Tahamtan Ahmadi, Maria Krevvata, Ke Zhang, Carla de Boer, Sanjay Vara, Tobias Kampfenkel, Véronique Vanquickelberghe, Jessica Vermeulen, Hervé Avet‐Loiseau, Pieter Sonneveld
How much of the research on Institut de Cancérologie de Bourgogne is open access?
ScholarIQopen access share
100%OPEN ACCESS